# Silo Pharma, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Silo Pharma, Inc.).

## Overview

Silo Pharma, Inc. is a U.S.-based developmental-stage biopharmaceutical company focused on licensing, developing, and advancing drug candidates for central nervous system and stress-related disorders. Its pipeline includes intranasal, implantable, and peptide-based programs, and the company also holds digital assets as part of a treasury strategy.

## Products & services

• SPC-15 intranasal treatment for PTSD and stress-induced anxiety
• SP-26 ketamine implant for fibromyalgia and chronic pain
• SPC-14 intranasal program for Alzheimer’s disease
• SPU-16 CNS-homing peptide for neuroinflammatory disease
• Licensing of proprietary drug delivery and IP rights

- **Lead therapeutic programs** (70%) — Development-stage drug candidates targeting PTSD, anxiety, fibromyalgia, and CNS disorders.
- **Drug delivery technology** (15%) — Intranasal and other delivery mechanisms used to improve targeting and onset of action.
- **Licensed intellectual property** (10%) — Exclusive and option-based rights to external inventions and patents supporting the pipeline.
- **Digital asset treasury** (5%) — Cryptocurrency holdings and related treasury activities outside the core therapeutics business.

- SPC-15 intranasal treatment for PTSD and stress-induced anxiety
- SP-26 ketamine implant for fibromyalgia and chronic pain
- SPC-14 intranasal program for Alzheimer’s disease
- SPU-16 CNS-homing peptide for neuroinflammatory disease
- Licensing of proprietary drug delivery and IP rights

## Customers

Silo Pharma does not sell commercial medicines at scale; its economic counterparties are primarily licensors, research institutions, and development partners that provide intellectual property, technology, or sponsored research support. If its programs advance, the eventual end customers would be patients and healthcare providers in neurology, psychiatry, pain management, and related specialty care.

- **IP licensors and research institutions** (primary) — Provide patents, compounds, or delivery technologies that Silo licenses to build its pipeline.
- **Clinical development partners** (primary) — Support preclinical, toxicology, and regulatory-enabling studies for candidate advancement.
- **Future specialty-care patients** (emerging) — Patients with PTSD, stress-induced anxiety, fibromyalgia, Alzheimer’s disease, or neuroinflammatory conditions who would use approved products.
- **Healthcare providers** (emerging) — Psychiatrists, neurologists, pain specialists, and other clinicians who would prescribe or administer therapies.

- Universities and research institutions that license IP to Silo
- Technology licensors providing drug delivery platforms
- Clinical and preclinical research partners supporting development
- Future patients with PTSD, anxiety, fibromyalgia, or CNS disease
- Healthcare providers and specialists who would prescribe approved therapies

## Geography

Silo Pharma is headquartered in the United States and conducts its business through U.S.-based corporate, regulatory, and research activities. Its development programs are global in scope because the company licenses intellectual property from external parties and seeks worldwide rights for some assets, but the disclosed operating footprint is primarily U.S.-centric.

- Headquartered in the United States
- Regulatory interactions are centered on the U.S. FDA
- Licensing and research rights may be worldwide for some programs
- Development work is driven by U.S.-based corporate operations
- No country-level revenue disclosure was provided in the excerpts

## Strategy

Silo Pharma’s strategy is to license or acquire external intellectual property, fund development, and advance a small number of differentiated CNS and pain programs toward regulatory milestones. It is also building a cryptocurrency treasury strategy, which adds a separate capital-allocation track alongside the therapeutics pipeline.

- **Advance SPC-15 through regulatory development** (short-term) — SPC-15 is the lead program and the clearest path to a clinical-stage asset.
- **Build a broader CNS and pain pipeline** (medium-term) — Multiple programs reduce dependence on a single asset and expand optionality.
- **License external IP and technology rights** (medium-term) — The company relies on external inventions to source differentiated candidates.
- **Develop digital asset treasury capabilities** (short-term) — The treasury strategy creates a separate investment framework and capital use case.

- Advance SPC-15 through IND-enabling work and FDA alignment
- Develop SP-26, SPC-14, and SPU-16 as follow-on pipeline assets
- Use intranasal and peptide delivery to improve targeting and tolerability
- License external IP from universities and researchers
- Allocate part of resources to digital assets and treasury management

## Risks

Silo Pharma faces the typical risks of a development-stage biotech company: clinical, regulatory, and intellectual property execution risk, with no assurance that its programs will reach approval or commercialization. The added cryptocurrency treasury strategy introduces market, custody, and execution risk, while the company’s small scale and Nasdaq listing dependence can affect financing flexibility and investor liquidity.

- **Pipeline development and regulatory risk** [high] — Drug candidates must clear preclinical, IND, and clinical hurdles before commercialization.
- **Intellectual property and licensing dependence** [high] — The business depends on rights from third parties and may face renewal, scope, or royalty constraints.
- **Cryptocurrency market and treasury execution risk** [high] — Digital assets can be volatile and operational mistakes in custody or trading can create losses.
- **Nasdaq listing and financing risk** [medium] — Maintaining exchange listing supports liquidity and access to capital for a pre-revenue biotech.
- **Competition in CNS and psychedelic medicine** [medium] — Other developers are pursuing similar indications, delivery methods, and assets.

- Clinical and regulatory failure could stop pipeline advancement
- Licensed IP may be limited by term, scope, or commercialization terms
- Biotech development requires capital before any product revenue
- Digital asset prices and staking outcomes can be highly volatile
- Nasdaq listing compliance affects liquidity and financing access

## Accounting

The most important accounting judgments are research and development expense timing, stock-based compensation, and the measurement of digital assets and short-term investments. Revenue is minimal and is recognized over time from a license arrangement, so reported sales can be small and not representative of operating progress.

- **Research and development expense recognition** — Can create volatility in quarterly operating results
- **Stock-based compensation** — Affects operating expenses and diluted share count
- **License revenue recognition** — Produces small, deferred revenue recognition rather than upfront sales
- **Digital asset accounting** — Can materially affect other income and balance sheet values

- R&D is expensed as incurred, affecting reported losses and cash burn
- Percentage-of-completion estimates affect in-process research expense
- Stock-based compensation depends on grant-date fair value estimates
- License revenue is recognized over the contract term, not upfront
- Digital asset holdings can create fair value or realized/unrealized gains and losses

---

*Last updated: 2026-04-29T04:58:37.177809+00:00*